Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Moodys
Mallinckrodt
Boehringer Ingelheim
McKesson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

DIHYDROERGOTAMINE MESYLATE Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Dihydroergotamine Mesylate, and what generic alternatives are available?

Dihydroergotamine Mesylate is a drug marketed by Hikma Pharms, Paddock Llc, Sagent Pharms Inc, and West-ward Pharms Int. and is included in four NDAs.

The generic ingredient in DIHYDROERGOTAMINE MESYLATE is dihydroergotamine mesylate. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.

Drug patent expirations by year for DIHYDROERGOTAMINE MESYLATE
Drug Prices for DIHYDROERGOTAMINE MESYLATE

See drug prices for DIHYDROERGOTAMINE MESYLATE

Recent Clinical Trials for DIHYDROERGOTAMINE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Satsuma Pharmaceuticals, Inc.Phase 3
Satsuma Pharmaceuticals, Inc.Phase 1
Impel NeuroPharma Inc.Phase 1

See all DIHYDROERGOTAMINE MESYLATE clinical trials

Pharmacology for DIHYDROERGOTAMINE MESYLATE
Medical Subject Heading (MeSH) Categories for DIHYDROERGOTAMINE MESYLATE
Synonyms for DIHYDROERGOTAMINE MESYLATE
(10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman mesylate
(10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman methanesulfonate
(6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxa
(6aR,9R)-N-((2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide
(6aR,9R)-N-((2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate
(6aR,9R)-N-((2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate
11032-41-0
511-12-6 (Parent)
6190-39-2
81AXN7R2QT
9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotaman-3',6',18-trione mesylate
9,10-Dihydroergotamine mesylate
9,10-dihydroergotamine methanesulfonate
910882-41-6
AC1L2FO7
AC1LAOVT
AC1Q6WD6
ADYPXRFPBQGGAH-UMYZUSPBSA-N
AKOS024282478
AN-21195
ANW-42737
C33H37N5O5.CH4O3S
CCG-39548
CHEBI:59756
CHEMBL1200517
CHEMBL1396675
CS-2903
CTK8B3562
D 2763
D.H.E. 45
D02211
D2633
DETMS
DHE-45
Dihydergot
Dihydroergotamine (mesylate)
Dihydroergotamine for peak identification, European Pharmacopoeia (EP) Reference Standard
Dihydroergotamine mesilate
Dihydroergotamine mesilate (JP17)
Dihydroergotamine mesilate, European Pharmacopoeia (EP) Reference Standard
Dihydroergotamine mesylate (USP)
Dihydroergotamine mesylate [USAN:USP]
Dihydroergotamine mesylate [USAN]
Dihydroergotamine mesylate, United States Pharmacopeia (USP) Reference Standard
Dihydroergotamine methanesulfonate
Dihydroergotamine methanesulfonate salt
Dihydroergotamine methanesulfonate salt, powder
Dihydroergotamine monomethanesulfonate
Dihytamine
EINECS 228-235-6
Ergotamine, 9,10-dihydro-, monomethanesulfonate (salt)
Ergotamine, dihydro, methanesulfonate (salt)
Ergotoman-3',6',18-trione,9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, monomethanesulfonate (salt)
EU-0100357
HMS1920G16
HMS2094K05
HMS2231H03
HMS3261G15
HMS3266C22
HMS3369K10
HMS501N14
HY-B0670A
I14-101170
LP00357
LS-64558
MFCD00058615
mide methanesulfonate
MLS002153175
MLS002207048
MolPort-003-666-163
MT 300
NCGC00261042-01
NSC-759848
NSC759848
Pharmakon1600-01500248
Prestwick_746
rboxamide methanesulfonate(salt)
SCHEMBL40843
SCHEMBL40844
SMR001230668
SPECTRUM1500248
SR-01000075382
SR-01000075382-1
SR-01000075382-3
SR-01000597746
SR-01000597746-1
ST056346
Tox21_500357
TR-021291
TRA0034972
UNII-81AXN7R2QT
Z1544404034

US Patents and Regulatory Information for DIHYDROERGOTAMINE MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma Pharms DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate INJECTABLE;INJECTION 206621-001 Sep 15, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
West-ward Pharms Int DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate INJECTABLE;INJECTION 040453-001 Jun 9, 2003 AP RX No No   Start Trial   Start Trial   Start Trial
Paddock Llc DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate INJECTABLE;INJECTION 040475-001 Apr 28, 2003 AP RX No No   Start Trial   Start Trial   Start Trial
Sagent Pharms Inc DIHYDROERGOTAMINE MESYLATE dihydroergotamine mesylate INJECTABLE;INJECTION 207264-001 Jul 11, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.